Zacks.com on MSN16h
KRYS Gets Positive CHMP Opinion for EU Approval of Skin Disease DrugKrystal Biotech receives positive CHMP opinion recommending the approval of Vyjuvek for treating dystrophic epidermolysis bullosa in the EU.
The European Medicines Agency’s (EMA) human medicines committee has recommended Krystal Biotech’s Vyjuvek (beremagene ...
Zacks Small Cap Research on MSN18h
LGND: First Steps into Cell & Gene TherapyLGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) reported 2024 financial and operational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback